David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
New First-in-Class ITP Therapy May Transform Clinical Practice: David Kuter, MD, DPhil
Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.